The Global Generic Drugs Market Will Reach $356.8bn In 2020 Predicts New Visiongain Report

07 September 2018
Pharma

A new report by visiongain predicts that the Global Generics Drugs market will reach $356.8bn in 2020. This forecast and others appear in Generic Drugs Market Forecast 2016-2026: Growth in Leading Regional and National Markets, published in April 2016. Visiongain is a business information provider based in London, UK.

This report examines the current and future trends in the growing generic drugs market. Population growth and changing demographics with increasing proportions of elderly people in most markets will enhance growth of the market. The rapid emergence of the middle-class in many emerging markets will also contribute to growth. Cost-pressures that encourage healthcare providers and governments to introduce policies to further encourage the use of generic drugs will further bring growth to the generics market over the years.
In this report, we examine in detail the global generic drugs market, and provide analyses and forecasts for regional and national markets. Historical revenues, where available, have also been added to strengthen our analysis and demonstrate how this market has changed. Qualitative analysis of the market is given, taking into account governmental policy and regulation, safety, features and more.

Visiongain’s report provides revenue forecasts to 2026 for the Generic Drugs market, including forecasts for leading regional and national markets: US, EU5 (Germany, UK, France, Italy and Spain), Asia-Pacific (China, Japan and India) as well as emerging markets (Brazil, Russia, Mexico, South Korea and Turkey). The report also discusses selected leading companies in the market. These companies include Teva, Mylan, Novartis (Sandoz), Sun Pharma, Pfizer, Abbott, Allergan, Fresenius Kabi, Sanofi and Aspen.

Generic Drugs Market Forecast 2016-2026: Growth in Leading Regional and National Markets adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.

Recent News

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever